| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Lindsay KL | |
| P433 | issue | 3 Suppl 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| P304 | page(s) | 71S-77S | |
| P577 | publication date | 1997-09-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Therapy of hepatitis C: overview | |
| P478 | volume | 26 |
| Q43001230 | A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection |
| Q44988872 | A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. |
| Q55017727 | Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy. |
| Q44878564 | Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes |
| Q24551046 | Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication |
| Q43709293 | Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III. |
| Q73629650 | Analysis of biochemical and virological efficacy of human lymphoblastoid interferon (IFN) in patients with compensated type C liver cirrhosis: comparative study between increase in individual IFN dose and prolonging of treatment period, using a mult |
| Q50686838 | Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C. |
| Q42989822 | Can HCV infection be cleared? |
| Q35621763 | Challenges in therapy of chronic hepatitis B. |
| Q45750469 | Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication |
| Q30580854 | Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP). |
| Q36491967 | Combination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy |
| Q50587922 | Combination therapy of chronic hepatitis C: an important step but not the final goal! |
| Q27469977 | Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treat |
| Q33988098 | Consensus among consensus conferences on management of hepatitis C: what we knew then and are still sure about, what we are newly sure about, and what we still need to know |
| Q45739562 | Current Views on Hepatitis C Virus Infection |
| Q35017769 | Current and future hepatitis C virus diagnostic testing: problems and advancements |
| Q78171521 | Current practice patterns of primary care physicians in the management of patients with hepatitis C |
| Q33809532 | Definition of response to antiviral therapy in chronic hepatitis C. |
| Q42991824 | Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse-transcriptase polymerase chain reaction. |
| Q42999898 | Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta |
| Q27469997 | Dynamics of Persistent TT Virus Infection, as Determined in Patients Treated with Alpha Interferon for Concomitant Hepatitis C Virus Infection |
| Q40822250 | Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. |
| Q24813993 | Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells |
| Q42990180 | Effect of interferon therapy on hepatitis C virus RNA in whole blood, plasma, and peripheral blood mononuclear cells. |
| Q43036511 | Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells |
| Q42989126 | Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients |
| Q28370506 | Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group |
| Q27469719 | Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy |
| Q50586689 | Firstline treatment for hepatitis C: combination interferon/ribavirin versus interferon monotherapy. |
| Q45752014 | Hepatitis C in the patient with human immunodeficiency virus infection |
| Q77720263 | Hepatitis C virus NS3/4A protease |
| Q35105688 | Hepatitis C virus genetic variability: pathogenic and clinical implications |
| Q27469808 | Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response |
| Q39455553 | Hepatitis C virus quantitation: optimization of strategies for detecting low-level viremia. |
| Q27469634 | Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo |
| Q27468916 | Hepatitis C virus: Promising discoveries and new treatments |
| Q33720568 | Hepatitis C virus: current understanding and prospects for future therapies |
| Q35105690 | Hepatitis C virus–cell interactions and their role in pathogenesis |
| Q33335254 | Hepatitis C. |
| Q45889715 | Hepatitis in haemophilia |
| Q24799492 | High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study |
| Q33756581 | Inflammation-induced cholestasis |
| Q34795057 | Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users |
| Q40578485 | Inhibition of hepatitis C virus IRES-mediated translation by small RNAs analogous to stem-loop structures of the 5'-untranslated region. |
| Q58325019 | Inhibition of the cyclooxygenase/lipoxygenase pathways to improve interferon alfa efficacy in chronic hepatitis C: A wrong track |
| Q42168851 | Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients |
| Q45142647 | Interferon-alpha (IFN-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway |
| Q60718595 | Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients |
| Q34517293 | Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. |
| Q42004459 | Interferons activate the p42/44 mitogen-activated protein kinase and JAK-STAT (Janus kinase-signal transducer and activator transcription factor) signalling pathways in hepatocytes: differential regulation by acute ethanol via a protein kinase C-dep |
| Q36485760 | Is interferon-beta an alternative treatment for chronic hepatitis C? |
| Q40000685 | Isolation and gene analysis of interferon alpha-resistant cell clones of the hepatitis C virus subgenome |
| Q39572121 | Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C. |
| Q33988105 | Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C. |
| Q42993893 | Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon |
| Q42995857 | Low virological response to interferon in children with chronic hepatitis C. |
| Q34740589 | Management of hepatitis C infection in renal transplant recipients |
| Q34422694 | Management of interferon therapy nonresponders |
| Q33983949 | Molecular biology of hepatitis C infection |
| Q43032247 | Monitoring response during a randomised controlled trial of escalating interferon dose for chronic hepatitis C infection: predictive value of quantitative and qualitative HCV RNA assays |
| Q33338255 | Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis C. |
| Q34256005 | Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine |
| Q34282823 | New animal models of hepatitis B and C. |
| Q34210684 | Overview of interferon therapy for chronic hepatitis C. |
| Q34481295 | Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. |
| Q33853655 | Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection |
| Q42999434 | Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C. |
| Q37050953 | Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors. |
| Q34728463 | Protein therapeutics: a summary and pharmacological classification |
| Q42998144 | Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C. |
| Q45752944 | Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I |
| Q72996749 | Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C |
| Q49216363 | Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C. |
| Q27469918 | Regulation of mRNA Translation and Cellular Signaling by Hepatitis C Virus Nonstructural Protein NS5A |
| Q34984083 | Retreatment of patients with chronic hepatitis C. |
| Q42999098 | Risk factors for development of hepatocellular carcinoma among Australians with hepatitis C: a case-control study |
| Q42994769 | Serum level of interleukin-4 is a possible marker of therapeutic response to interferon treatment in patients with chronic hepatitis C. |
| Q43046673 | Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis |
| Q42822570 | Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease |
| Q33444662 | Test validity of periodic liver function tests in a population of Japanese male bank employees |
| Q33801327 | The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy |
| Q45297557 | The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States |
| Q33801346 | The non-structural 5A protein of hepatitis C virus |
| Q73390774 | The protective effect of glycyrrhizin on anti-Fas antibody-induced hepatitis in mice |
| Q33860756 | The role of the hepatitis C virus glycoproteins in infection. |
| Q28571688 | The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver |
| Q45855058 | Therapy for chronic hepatitis B and C infection in haemophilia |
| Q36382235 | Therapy of hepatitis C: from empiricism to eradication |
| Q35046558 | Treatment of chronic hepatitis C in nonresponders to previous therapy |
| Q33809610 | Treatment of chronic hepatitis C: comparative virologic response rates among the different interferons |
| Q39343958 | Treatment of hepatitis C cryoglobulinemia: mission and challenges |
Search more.